Allergy Therapeutics plc (AIM: AGY), a biotechnology company that specialises in allergy vaccines, on Tuesday announced interim top-line results from the G306 Phase III trial of Grass MATA MPL, its subcutaneous allergen-specific immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. The trial met its primary endpoint, showing a highly statistically significant reduction in Combined Symptom & Medication Score (CSMS) in the active treatment group compared to placebo (p≤0.0024).
The adaptive trial design allowed for an interim analysis, leading to the trial's early termination for success. Full analysis, including treatment effect data and secondary endpoint analysis, is expected in mid-December. The G306 trial, conducted in the US and Europe at 89 sites, demonstrated the efficacy and safety of Grass MATA MPL.
Preparations for the G308 paediatric study are underway to meet German regulatory requirements and an approved Paediatric Investigation Plan (PIP). Allergy Therapeutics focuses on the treatment and diagnosis of allergic disorders, with a broad product pipeline, including vaccines for grass, tree, house dust mite and peanut allergies.
Grass MATA MPL aims to address allergic rhinitis and rhinoconjunctivitis, offering a potential solution for seasonal and perennial allergies. The product uses an allergoid modified with glutaraldehyde and includes MPL as an adjuvant to enhance the immunogenic effect.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration